VIMLAYAH
Live / Applied — First extension granted (statement of use) (as of 20 Feb 2026)
What this means for you
Not registered yet, but its 19 Dec 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98912354
- Mark type
- Stylized text
- Filed
- 19 Dec 2024
- Published for opposition
- 22 Jul 2025
- Attorney of record
- Chelseaa Larsen
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; pharmaceutical preparations for the prevention and treatment of lysosomal storage diseases
- Class 042 — Scientific and technological services: Scientific research, pharmaceutical research, and medical research; technical consultation and product development for investigators and researchers and neurologists in the field of development of pharmaceuticals
Owner
- Denali Therapeutics Inc., South San Francisco, CA, US
- Denali Therapeutics Inc., South San Francisco, CA, US
Prosecution history
- 21 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Feb 2026 — SOU EXTENSION 1 GRANTED
- 20 Feb 2026 — SOU EXTENSION 1 FILED
- 20 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 16 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 22 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 22 Jul 2025 — PUBLISHED FOR OPPOSITION
- 16 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 17 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 16 Jun 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 16 Jun 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 16 Jun 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 09 Jun 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 09 Jun 2025 — NON-FINAL ACTION E-MAILED
- 09 Jun 2025 — NON-FINAL ACTION WRITTEN